Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anus Neoplasms | 10 | 2022 | 414 | 0.770 |
Why?
|
| Rectal Neoplasms | 17 | 2017 | 1220 | 0.760 |
Why?
|
| Chemoradiotherapy | 13 | 2022 | 2001 | 0.620 |
Why?
|
| Fluorouracil | 22 | 2022 | 1947 | 0.460 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2022 | 2123 | 0.410 |
Why?
|
| Radiotherapy Dosage | 25 | 2016 | 3939 | 0.350 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2022 | 5448 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2022 | 10180 | 0.340 |
Why?
|
| Adenocarcinoma | 14 | 2017 | 7758 | 0.300 |
Why?
|
| Deoxycytidine | 12 | 2013 | 1352 | 0.290 |
Why?
|
| Radiotherapy | 8 | 2011 | 1827 | 0.280 |
Why?
|
| Pancreatic Neoplasms | 10 | 2016 | 5168 | 0.280 |
Why?
|
| Re-Irradiation | 2 | 2018 | 164 | 0.260 |
Why?
|
| Brachytherapy | 6 | 2014 | 991 | 0.240 |
Why?
|
| Radiation Injuries | 5 | 2012 | 1440 | 0.240 |
Why?
|
| Capecitabine | 12 | 2016 | 387 | 0.230 |
Why?
|
| Pelvic Neoplasms | 2 | 2018 | 201 | 0.220 |
Why?
|
| Stomach Neoplasms | 5 | 2012 | 2271 | 0.180 |
Why?
|
| Combined Modality Therapy | 22 | 2016 | 8884 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2022 | 16299 | 0.180 |
Why?
|
| Iridium Radioisotopes | 3 | 2006 | 57 | 0.170 |
Why?
|
| Radiation Oncologists | 1 | 2019 | 32 | 0.160 |
Why?
|
| Community Health Centers | 1 | 2019 | 50 | 0.160 |
Why?
|
| Palliative Care | 6 | 2011 | 2136 | 0.160 |
Why?
|
| Middle Aged | 49 | 2018 | 87562 | 0.160 |
Why?
|
| Aged, 80 and over | 30 | 2016 | 30262 | 0.150 |
Why?
|
| Aged | 43 | 2018 | 71343 | 0.150 |
Why?
|
| Radiotherapy, Conformal | 4 | 2016 | 874 | 0.150 |
Why?
|
| Preoperative Care | 6 | 2013 | 1507 | 0.140 |
Why?
|
| Adult | 42 | 2018 | 78876 | 0.140 |
Why?
|
| Cisplatin | 4 | 2022 | 2449 | 0.140 |
Why?
|
| Male | 50 | 2018 | 124253 | 0.130 |
Why?
|
| Peer Review, Health Care | 1 | 2016 | 32 | 0.130 |
Why?
|
| Female | 52 | 2018 | 143882 | 0.130 |
Why?
|
| Organs at Risk | 2 | 2016 | 552 | 0.130 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2008 | 292 | 0.130 |
Why?
|
| Survival Rate | 13 | 2018 | 12270 | 0.120 |
Why?
|
| Retrospective Studies | 27 | 2022 | 38849 | 0.120 |
Why?
|
| Neoplasm Staging | 14 | 2016 | 13778 | 0.120 |
Why?
|
| Disease-Free Survival | 12 | 2015 | 10023 | 0.120 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2015 | 82 | 0.120 |
Why?
|
| Spleen | 1 | 2016 | 681 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2016 | 206 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 8 | 2009 | 1319 | 0.120 |
Why?
|
| Radiation Protection | 2 | 2012 | 199 | 0.120 |
Why?
|
| Follow-Up Studies | 14 | 2018 | 14838 | 0.120 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 678 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2006 | 358 | 0.110 |
Why?
|
| Thrombocytosis | 1 | 2015 | 136 | 0.110 |
Why?
|
| Treatment Outcome | 22 | 2017 | 33152 | 0.110 |
Why?
|
| Humans | 59 | 2022 | 262965 | 0.100 |
Why?
|
| Dilatation | 1 | 2012 | 86 | 0.100 |
Why?
|
| Genitalia, Female | 1 | 2012 | 73 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2008 | 3933 | 0.100 |
Why?
|
| Duodenum | 1 | 2012 | 148 | 0.100 |
Why?
|
| Survival Analysis | 11 | 2014 | 9153 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2016 | 613 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2008 | 2249 | 0.090 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 898 | 0.090 |
Why?
|
| Radiation Oncology | 1 | 2016 | 550 | 0.090 |
Why?
|
| Anal Canal | 3 | 2013 | 239 | 0.090 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2011 | 196 | 0.080 |
Why?
|
| Abdominal Neoplasms | 1 | 2011 | 240 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2012 | 6789 | 0.080 |
Why?
|
| Metformin | 1 | 2013 | 389 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 3763 | 0.080 |
Why?
|
| Disease Progression | 9 | 2016 | 6746 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 595 | 0.080 |
Why?
|
| Patient Positioning | 1 | 2010 | 191 | 0.080 |
Why?
|
| Sacrum | 1 | 2009 | 134 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2011 | 496 | 0.070 |
Why?
|
| Radiation Dosage | 4 | 2016 | 1011 | 0.070 |
Why?
|
| Spinal Fractures | 1 | 2009 | 136 | 0.070 |
Why?
|
| Induction Chemotherapy | 3 | 2016 | 669 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2011 | 730 | 0.070 |
Why?
|
| Heart | 2 | 2011 | 1169 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2009 | 612 | 0.070 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2007 | 144 | 0.070 |
Why?
|
| Ampulla of Vater | 1 | 2007 | 154 | 0.070 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 5206 | 0.070 |
Why?
|
| Lymphatic Metastasis | 7 | 2011 | 4901 | 0.070 |
Why?
|
| Texas | 6 | 2019 | 6275 | 0.070 |
Why?
|
| Radiometry | 1 | 2011 | 994 | 0.060 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2009 | 276 | 0.060 |
Why?
|
| Colorectal Neoplasms | 2 | 2014 | 3572 | 0.060 |
Why?
|
| Bevacizumab | 3 | 2016 | 939 | 0.060 |
Why?
|
| Mitomycin | 2 | 2022 | 207 | 0.060 |
Why?
|
| Drug Administration Schedule | 4 | 2013 | 3467 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2006 | 265 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 904 | 0.060 |
Why?
|
| Colectomy | 1 | 2006 | 284 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 6158 | 0.060 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2016 | 388 | 0.060 |
Why?
|
| Breast | 1 | 2010 | 1335 | 0.060 |
Why?
|
| Liver Neoplasms | 3 | 2011 | 4633 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2000 | 5440 | 0.050 |
Why?
|
| Prognosis | 7 | 2018 | 22048 | 0.050 |
Why?
|
| Fatigue | 1 | 2009 | 1261 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1387 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 4 | 2013 | 5139 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2016 | 1312 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 1442 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2009 | 2087 | 0.050 |
Why?
|
| Incidence | 4 | 2018 | 5705 | 0.050 |
Why?
|
| Lung Neoplasms | 3 | 2000 | 11572 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2002 | 328 | 0.040 |
Why?
|
| Carcinoma | 1 | 2011 | 2568 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2012 | 2239 | 0.040 |
Why?
|
| Time Factors | 5 | 2016 | 12676 | 0.040 |
Why?
|
| Antineoplastic Agents | 6 | 2013 | 14445 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 2090 | 0.040 |
Why?
|
| Neoplasms | 2 | 2019 | 15604 | 0.040 |
Why?
|
| Organoplatinum Compounds | 2 | 2011 | 695 | 0.040 |
Why?
|
| Bile Duct Neoplasms | 1 | 2002 | 486 | 0.040 |
Why?
|
| Cholangiocarcinoma | 1 | 2002 | 490 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2007 | 700 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2015 | 2004 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2009 | 4247 | 0.030 |
Why?
|
| Gastrectomy | 2 | 2011 | 473 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 5000 | 0.030 |
Why?
|
| Equipment Design | 2 | 2012 | 1171 | 0.030 |
Why?
|
| Pain | 3 | 2009 | 1661 | 0.030 |
Why?
|
| Breath Holding | 1 | 2015 | 44 | 0.030 |
Why?
|
| Quality of Life | 1 | 2010 | 4651 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 480 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 188 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2008 | 1407 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 85 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2012 | 12972 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 476 | 0.030 |
Why?
|
| Colostomy | 1 | 2013 | 78 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 335 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 393 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2012 | 162 | 0.030 |
Why?
|
| Sex Factors | 2 | 2009 | 2115 | 0.030 |
Why?
|
| Remission Induction | 2 | 2009 | 3595 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 2240 | 0.020 |
Why?
|
| Young Adult | 4 | 2013 | 21764 | 0.020 |
Why?
|
| Dehydration | 1 | 2011 | 88 | 0.020 |
Why?
|
| Radiography | 1 | 2015 | 1875 | 0.020 |
Why?
|
| Sarcoma | 1 | 2002 | 1810 | 0.020 |
Why?
|
| Risk Factors | 4 | 2009 | 17420 | 0.020 |
Why?
|
| Anorexia | 1 | 2011 | 147 | 0.020 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2012 | 206 | 0.020 |
Why?
|
| Vagina | 1 | 2012 | 326 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2013 | 560 | 0.020 |
Why?
|
| Nausea | 1 | 2011 | 534 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3364 | 0.020 |
Why?
|
| Sleep Stages | 1 | 2009 | 80 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 3341 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 928 | 0.020 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2010 | 129 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1668 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2011 | 2413 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 441 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 2009 | 139 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 991 | 0.020 |
Why?
|
| Jejunostomy | 1 | 2008 | 54 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2007 | 249 | 0.020 |
Why?
|
| Pelvis | 1 | 2009 | 377 | 0.020 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2007 | 124 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 95 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 1255 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2008 | 186 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 36 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 907 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 174 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 533 | 0.020 |
Why?
|
| Digestive System | 1 | 2006 | 113 | 0.020 |
Why?
|
| Surface Properties | 1 | 2006 | 174 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2006 | 166 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2006 | 227 | 0.020 |
Why?
|
| Radiology, Interventional | 1 | 2006 | 140 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 963 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 544 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 675 | 0.010 |
Why?
|
| Washington | 1 | 2003 | 75 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 1291 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2007 | 435 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 7588 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2008 | 466 | 0.010 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 10520 | 0.010 |
Why?
|
| Kidney | 1 | 2011 | 2136 | 0.010 |
Why?
|
| Pyridines | 1 | 2009 | 1285 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6035 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2007 | 808 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 834 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 1387 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 2000 | 171 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 600 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 1316 | 0.010 |
Why?
|
| Depression | 1 | 2010 | 1702 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5811 | 0.010 |
Why?
|
| Patient Selection | 1 | 2004 | 2014 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 5322 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 2798 | 0.010 |
Why?
|
| Weight Loss | 1 | 2000 | 631 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 2000 | 649 | 0.010 |
Why?
|
| Survivors | 1 | 2000 | 1016 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 9239 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 3570 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 4350 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2000 | 4842 | 0.000 |
Why?
|